“…When compared with GNRI, most patients that were divided by an Alb level cutoff were categorized as being in the Alb-high group (134 and 41 in high and low groups, respectively, for Alb; vs. 109 and 66 in high and low groups, respectively, for GNRI). Considering the substantial contribution of the Alb level to predicting OS in this study, and recent evidence on the efficacy of complex biomarkers, including serum Alb [21,22], the GNRI was therefore selected for this study. With regard to prolonged TTCR, the following were revealed in univariate analysis to be independent prognostic factors when initial treatment was started: existence of symptoms (HR: 1.87, 95% CI: 1.16-3.03), upfront AA treatment (HR: 0.38, 95% CI: 0.24-0.60), low CRP level (HR: 0.45, 95% CI: 0.28-0.74), and high GNRI (HR: 0.44, 95% CI: 0.28-0.69).…”